{
  "chapters": [
    {
      "number": 1,
      "title": "Intro",
      "durationSec": 31,
      "positionSec": 0
    },
    {
      "number": 2,
      "title": "Begrüßung",
      "durationSec": 47,
      "positionSec": 31
    },
    {
      "number": 3,
      "title": "Hintergrundinformationen",
      "durationSec": 238,
      "positionSec": 79
    },
    {
      "number": 4,
      "title": "Neues zur Risikotabelle",
      "durationSec": 1245,
      "positionSec": 318
    },
    {
      "number": 5,
      "title": "Situation in Deutschland",
      "durationSec": 495,
      "positionSec": 1563
    },
    {
      "number": 6,
      "title": "Dispersion, Zufall und neue Varianten",
      "durationSec": 383,
      "positionSec": 2058
    },
    {
      "number": 7,
      "title": "B1117 und Kinder",
      "durationSec": 306,
      "positionSec": 2442
    },
    {
      "number": 8,
      "title": "Situation in den Bundesländern",
      "durationSec": 515,
      "positionSec": 2748
    },
    {
      "number": 9,
      "title": "Schneesturm in Bielefeld",
      "durationSec": 433,
      "positionSec": 3264
    },
    {
      "number": 10,
      "title": "Pollenflug",
      "durationSec": 186,
      "positionSec": 3698
    },
    {
      "number": 11,
      "title": "Die Pandemie vorhersagen",
      "durationSec": 608,
      "positionSec": 3885
    },
    {
      "number": 12,
      "title": "Situation im Ausland",
      "durationSec": 726,
      "positionSec": 4494
    },
    {
      "number": 13,
      "title": "Impfkampagne und Verfügbarkeit von Impfstoffen",
      "durationSec": 744,
      "positionSec": 5220
    },
    {
      "number": 14,
      "title": "Impfreihenfolge",
      "durationSec": 299,
      "positionSec": 5965
    },
    {
      "number": 15,
      "title": "Impfsimulator",
      "durationSec": 350,
      "positionSec": 6264
    },
    {
      "number": 16,
      "title": "Digitale Impfquotenmonitoring",
      "durationSec": 288,
      "positionSec": 6615
    },
    {
      "number": 17,
      "title": "AstraZeneca und die Skeptiker",
      "durationSec": 580,
      "positionSec": 6904
    },
    {
      "number": 18,
      "title": "Neuer Impfstoff von Johnson & Johnson",
      "durationSec": 423,
      "positionSec": 7484
    },
    {
      "number": 19,
      "title": "Human Challgenges",
      "durationSec": 696,
      "positionSec": 7907
    },
    {
      "number": 20,
      "title": "Auswirkung von Impfungen auf Long Covid",
      "durationSec": 279,
      "positionSec": 8604
    },
    {
      "number": 21,
      "title": "Wahrscheinlichkeiten von Hospitalisierung und Tod",
      "durationSec": 534,
      "positionSec": 8883
    },
    {
      "number": 22,
      "title": "Schnelltests und Testläufe",
      "durationSec": 1024,
      "positionSec": 9418
    },
    {
      "number": 23,
      "title": "Ausklang",
      "durationSec": 343,
      "positionSec": 10442
    }
  ]
}